Montelukast sodium combined with budesonide inhibits asthma inflammatory response through the p38MAPK pathway
Objective:To investigate the effect and mechanism of montelukast sodium combined with budesonide on bronchial asthma(BA).Methods:A total of 24 male BALB/C mice were selected and randomly divided into control group,model group,montelukast sodium monotherapy group,inhaled budesonide monotherapy group,and montelukast sodium+inhaled budesonide combined therapy group.The control group and model group each had 6 mice,while the other groups had 4 mice.Except for the control group,all other groups of mice were constructed with the OVA method to establish mouse asthma models.After successful modeling,corresponding interventions were performed on each group of mice.After the intervention,hematoxylin eosin(HE)staining was used to observe the morphological changes in the airway tissue of each group of mice;Enzyme linked immunosorbent assay(ELISA)was used to measure the level of Interleukin-5(IL-5)in Bronchoalveolar lavage fluid;Western blot(WB)was used to detect changes in the expression of p38 mitogen-activated protein kinase(p38MAPK)signaling pathway protein in lung tissue.Results:Compared with the Control group,the model group,montelukast sodium monotherapy group,inhaled budesonide monotherapy group,and montelukast sodium+inhaled budesonide combined therapy group all showed mucosal tissue thickening and significant inflammatory cell infiltration in the airway of mice,but the combined therapy group was the least severe;Compared with the Model group,the montelukast sodium monotherapy group,the inhaled budesonide monotherapy group,and the montelukast sodium+inhaled budesonide combined therapy group all showed varying degrees of decrease in IL-5 levels in the alveolar lavage fluid of mice(P<0.01).This indicates that asthma drug therapy can alleviate the disease status of mice by suppressing pulmonary inflammatory reactions;Compared with the monotherapy group of montelukast sodium and the monotherapy group of inhaled budesonide,the combined therapy group of montelukast sodium and inhaled budesonide significantly reduced the level of IL-5 in the alveolar lavage fluid of mice(paired t-test P<0.01 and paired t-test P>0.05);The levels of phosphorylated p38 mitogen activated protein kinase(P-p38 MAPK)in the lung tissue of mice in the montelukast sodium+inhaled budesonide combined therapy group were significantly lower than those in the montelukast sodium monotherapy group(P<0.05).Conclusion:Combined administration can effectively improve the occurrence and development of inflammatory response in asthma,and its mechanism may be related to the inhibition of p38MAPK phosphorylation activation in vivo.
万方数据
维普
